Beacon Pointe Advisors’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $73.4M | Sell |
61,241
-815
| -1% | -$833K | 0.34% | 66 |
|
|
2026
Q1 | $57.1M | Buy |
62,056
+16,929
| +38% | +$17.2M | 0.3% | 73 |
|
|
2025
Q4 | $48.5M | Buy |
45,127
+1,314
| +3% | +$1.26M | 0.34% | 65 |
|
|
2025
Q3 | $33.4M | Sell |
43,813
-1,415
| -3% | -$1.05M | 0.28% | 75 |
|
|
2025
Q2 | $35.3M | Sell |
45,228
-34,192
| -43% | -$26.6M | 0.37% | 52 |
|
|
2025
Q1 | $65.6M | Buy |
79,420
+9,502
| +14% | +$7.91M | 0.74% | 27 |
|
|
2024
Q4 | $54M | Buy |
69,918
+12,334
| +21% | +$10.2M | 0.6% | 35 |
|
|
2024
Q3 | $51M | Buy |
57,584
+7,261
| +14% | +$6.53M | 0.59% | 36 |
|
|
2024
Q2 | $45.6M | Buy |
50,323
+6,118
| +14% | +$4.89M | 0.54% | 39 |
|
|
2024
Q1 | $34.4M | Sell |
44,205
-21,906
| -33% | -$15.6M | 0.38% | 50 |
|
|
2023
Q4 | $38.5M | Buy |
66,111
+132
| +0.2% | +$77K | 0.46% | 42 |
|
|
2023
Q3 | $35.4M | Buy |
65,979
+12,136
| +23% | +$6.25M | 0.44% | 44 |
|
|
2023
Q2 | $25.3M | Sell |
53,843
-17,010
| -24% | -$7.13M | 0.41% | 55 |
|
|
2023
Q1 | $24.3M | Buy |
70,853
+30,607
| +76% | +$10.3M | 0.41% | 56 |
|
|
2022
Q4 | $14.7M | Buy |
40,246
+10,506
| +35% | +$3.72M | 0.29% | 86 |
|
|
2022
Q3 | $9.62M | Sell |
29,740
-10
| -0% | -$3.17K | 0.22% | 105 |
|
|
2022
Q2 | $9.65M | Buy |
29,750
+815
| +3% | +$245K | 0.2% | 116 |
|
|
2022
Q1 | $8.29M | Buy |
28,935
+9,317
| +47% | +$2.4M | 0.11% | 183 |
|
|
2021
Q4 | $5.42M | Sell |
19,618
-854
| -4% | -$216K | 0.14% | 136 |
|
|
2021
Q3 | $4.73M | Buy |
20,472
+8,033
| +65% | +$1.98M | 0.12% | 177 |
|
|
2021
Q2 | $2.85M | Buy |
12,439
+4,888
| +65% | +$982K | 0.1% | 178 |
|
|
2021
Q1 | $1.41M | Sell |
7,551
-529
| -7% | -$103K | 0.09% | 176 |
|
|
2020
Q4 | $1.36M | Buy |
8,080
+1,387
| +21% | +$207K | 0.09% | 166 |
|
|
2020
Q3 | $991K | Sell |
6,693
-622
| -9% | -$96.3K | 0.1% | 166 |
|
|
2020
Q2 | $1.2M | Buy |
7,315
+1,102
| +18% | +$169K | 0.12% | 146 |
|
|
2020
Q1 | $861K | Buy |
6,213
+1,832
| +42% | +$252K | 0.14% | 139 |
|
|
2019
Q4 | $578K | Sell |
4,381
-231
| -5% | -$26.8K | 0.18% | 118 |
|
|
2019
Q3 | $517K | Sell |
4,612
-360
| -7% | -$40.1K | 0.22% | 100 |
|
|
2019
Q2 | $553K | Buy |
4,972
+45
| +0.9% | +$5.3K | 0.2% | 112 |
|
|
2019
Q1 | $638K | Sell |
4,927
-250
| -5% | -$30.4K | 0.24% | 101 |
|
|
2018
Q4 | $600K | Buy |
+5,177
| New | +$578K | 0.36% | 79 |
|
Other funds holding LLY
Beacon Pointe Advisors's LLY Position: Q2 2026 in Review
Beacon Pointe Advisors reduced its Eli Lilly (LLY) stake by 1.3% in Q2 2026, selling an estimated $833K and leaving 61,241 shares worth $73.4M. The position accounts for 0.34% of the portfolio, ranked #66.
Beacon Pointe Advisors first reported a position in LLY in Q4 2018 and has held it in 31 quarters since. 4,626 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Beacon Pointe Advisors held 61,241 shares of Eli Lilly worth $73.4M as of Q2 2026.
- Beacon Pointe Advisors sold 815 Eli Lilly shares in Q2 2026, an estimated $833K.
- Eli Lilly made up 0.34% of Beacon Pointe Advisors's portfolio in Q2 2026, its #66 holding.
- Beacon Pointe Advisors first reported a position in Eli Lilly in Q4 2018 and has held it in 31 quarters since.
- 4,626 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Beacon Pointe Advisors's 13F filing for Q2 2026, filed 18 Aug 2026.